http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Keystone, E C,Genovese, M C,Klareskog, L,Hsia, E C,Hall, S T,Miranda, P C,Pazdur, J,Bae, S-C,Palmer, W,Zrubek, J,Wiekowski, M,Visvanathan, S,Wu, Z,Rahman, M U BMJ Publishing Group 2009 Annals of the Rheumatic Diseases Vol.68 No.6
<P><B>Objective:</B></P><P>The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy.</P><P><B>Methods:</B></P><P>Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n = 133), golimumab 100 mg injections plus placebo capsules (group 2, n = 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n = 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n = 89). Injections were administered subcutaneously every 4 weeks. The co-primary endpoints were the proportion of patients with 20% or greater improvement in the American College of Rheumatology criteria (ACR20) at week 14 and the change from baseline in the health assessment questionnaire-disability index (HAQ-DI) score at week 24.</P><P><B>Results:</B></P><P>The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group, 55.1% (p = 0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively. During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.</P><P><B>Conclusion:</B></P><P>The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.</P>
White, H,Deprez, L,Corbisier, P,Hall, V,Lin, F,Mazoua, S,Trapmann, S,Aggerholm, A,Andrikovics, H,Akiki, S,Barbany, G,Boeckx, N,Bench, A,Catherwood, M,Cayuela, J-M,Chudleigh, S,Clench, T,Colomer, D,Dar Nature Publishing Group 2015 Leukemia Vol.29 No.2
<P>Serial quantification of <I>BCR–ABL1</I> mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of <I>BCR–ABL1</I> (e14a2 mRNA fusion)<I>, BCR</I> and <I>GUSB</I> transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 10<SUP>6</SUP>, 1.08±0.11 × 10<SUP>5</SUP>, 1.03±0.10 × 10<SUP>4</SUP>, 1.02±0.09 × 10<SUP>3</SUP>, 1.04±0.10 × 10<SUP>2</SUP> and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 <I>BCR–ABL1</I> testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 <I>BCR–ABL1</I> and three control genes (<I>ABL1, BCR</I> and <I>GUSB</I>). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).</P>
New γ -ray transitions observed in Ne19 with implications for the O15(α,γ)Ne19 reaction rate
Hall, M. R.,Bardayan, D. W.,Baugher, T.,Lepailleur, A.,Pain, S. D.,Ratkiewicz, A.,Ahn, S.,Allen, J. M.,Anderson, J. T.,Ayangeakaa, A. D.,Blackmon, J. C.,Burcher, S.,Carpenter, M. P.,Cha, S. M.,Chae, K American Physical Society 2019 Physical Review C Vol.99 No.3
An unusual finding of the pectoralis major muscle: decussation of sternal fibers across the midline
Halle Burley,Georgi P. Georgiev,Joe Iwanaga,Aaron S. Dumont,R. Shane Tubbs 대한해부학회 2020 Anatomy & Cell Biology Vol.53 No.4
Variations of the pectoralis major muscle are commonly seen. However, during the routine dissection of an adult male cadaver, an apparently uncommon muscular variant was identified. In this cadaver, the sternal heads of the left and right pectoralis muscles crossed the midline and interdigitated with one another. In addition, the clavicular heads of both pectoralis major muscles were separated from the remaining parts of the muscles. Such anatomical variants such be kept in mind by clinicians and surgeons during patient evaluation and treatment.
Key Ne19 States Identified Affecting γ -Ray Emission from F18 in Novae
Hall, M. R.,Bardayan, D. W.,Baugher, T.,Lepailleur, A.,Pain, S. D.,Ratkiewicz, A.,Ahn, S.,Allen, J. M.,Anderson, J. T.,Ayangeakaa, A. D.,Blackmon, J. C.,Burcher, S.,Carpenter, M. P.,Cha, S. M.,Chae, K American Physical Society 2019 Physical Review Letters Vol.122 No.5
INSURANCE MARKET DEVELOPMENT AND MACROECONOMIC INTERACTIONS IN TWENTY-SIX COUNTRIES
RUDRA P. PRADHAN,MAK B. ARVIN,JOHN H. HALL,NEVILLE R. NORMAN 중앙대학교 경제연구소 2017 Journal of Economic Development Vol.42 No.4
This paper examines the cointegrating and causal relationships between insurance market development (IMD) and economic growth based on panel-data estimation techniques. It also investigates the dynamic interrelationships amongst a number of important macroeconomic variables on IMD-growth nexus. The sample consists of 26 countries observed over the period 1980-2013. We use six different indicators of IMD, covered under both insurance density and insurance penetration, to validate the robustness of our results. Our findings affirm a long-run equilibrium relationship between insurance market development, economic growth, and six other macroeconomic variables selected, namely broad money supply (relative to national income), real interest rates, inflation rates, urban population growth, youth dependency ratios, and government consumption expenditure (relative to national income). We use a panel vector auto-regression model to examine the nature of Granger causality among the variables. Most significantly, we find that IMD and some macroeconomic variables Granger-cause economic growth in the long run, irrespective of which measure of IMD we use.
RUDRA P. PRADHAN,MAK B. ARVIN,MAHENDHIRAN NAIR,JOHN H. HALL 중앙대학교 경제연구소 2022 Journal of Economic Development Vol.47 No.1
This paper examines the short-term and long-term dynamics between public sector debt, economic openness, and economic growth in European countries between 1990 and 2018. Using the panel vector error correction model, we find that both public debt and economic openness contribute to long-term economic growth in European countries. The empirical analysis also shows that there are strong endogenous links between public debt, economic openness and economic growth in Europe in the short run. These relationships suggest that governments in Europe should give careful attention to the co-curation of macroeconomic policies pertaining to public sector spending/taxation, economic openness, and economic growth.